### ğŸ«€ Cardiology: Brugada Syndrome Diagnosis

#### âœ… True Statements
1. **Brugada syndrome** is an **inherited arrhythmia disorder** characterized by a surface **electrocardiogram (ECG) pattern of right bundle branch block (RBBB) with â‰¥â€¯2â€‘mm STâ€‘segment elevation in the anterior precordial leads (Vâ‚â€“Vâ‚ƒ).**
2. Patients with **Brugada syndrome** are at increased risk for **syncope, ventricular fibrillation, or sudden cardiac death during sleep or when febrile or otherwise ill.**
3. **Brugada syndrome** occurs **more frequently in individuals of South Asian descent** than in other populations.
4. In young patients, **arrhythmogenic right ventricular cardiomyopathy (ARVC)** typically causes **exertional syncope** and shows **anterior precordial repolarization abnormalities with or without epsilon waves** on ECG, distinguishing it from Brugada syndrome.
5. **Hypertrophic cardiomyopathy (HCM)**â€“related syncope is usually **exertional** and is associated with **left ventricular hypertrophy and repolarization abnormalities** on ECG, differentiating it from Brugada syndrome.

#### ğŸ’¬ Extra
1. The classic Brugada ECG pattern is a **covedâ€‘type STâ€‘segment elevation** followed by a negative T wave in leads Vâ‚â€“Vâ‚ƒ.
2. **Fever** exacerbates sodiumâ€‘channel dysfunction in Brugada syndrome, unmasking the diagnostic ECG changes and precipitating malignant arrhythmias.
3. Pathogenic variants in the **SCN5A sodiumâ€‘channel gene** explain the ethnic clustering of Brugada syndrome.
4. **Epsilon waves** are lowâ€‘amplitude signals at the terminal portion of the QRS complex and are hallmarks of ARVC.
5. Deep Tâ€‘wave inversions and highâ€‘voltage QRS complexes are typical ECG findings in HCM.

#### ğŸ·ï¸ Tags
#Cardiology #AmbulatoryCare #PatientUnder25 #BrugadaSyndrome #Syncope #Arrhythmia

#### ğŸ“š Reference
MKSAPÂ 19: CardiovascularÂ Medicine â€” Arrhythmias, BrugadaÂ Syndrome

#### ğŸ†” Question ID
CVVDX24055

#### ğŸ•’ Last Updated
FebruaryÂ 2025

---

#### ğŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Arrhythmias, Inherited Syndromes Characterized by Sudden Cardiac Death

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements
1. Patients **younger than 40â€¯years** without ischemic or structural heart disease who experience **unexplained cardiac arrest, nearâ€‘drowning, exerciseâ€‘related syncope, or recurrent highâ€‘risk syncope** should be evaluated for **inherited arrhythmia or cardiomyopathy syndromes**.
2. **Unexplained premature death (<35â€¯years)** or **sudden death (<40â€¯years)** in a firstâ€‘degree relative warrants suspicion for an **inherited arrhythmia syndrome** and prompts **specialist referral with genetic counseling and testing**.
3. The diagnosis of **inherited arrhythmia syndromes** is complicated by **variable penetrance and expressivity**.
4. **Genetic LQTS** affects **1 in 1000â€“5000 persons**, but a **prolonged QTc (>440â€¯ms in men, >460â€¯ms in women) alone** is **insufficient for diagnosis** because the QT interval is variable and can be prolonged by **medications, structural heart disease, or electrolyte disturbances**.
5. Initial treatment of **genetic LQTS** includes **Î²â€‘blocker therapy** and **avoidance of QTâ€‘prolonging drugs**; selected patients may require an **implantable cardioverterâ€‘defibrillator, surgical sympathectomy, or exercise restriction**.
6. **Brugada syndrome** is identified by **â‰¥2â€¯mm Jâ€‘point elevation with downsloping STâ€‘segment coving in leads V1â€“V3**, occurs more frequently in persons of **Asian descent**, and is associated with **nightâ€‘time arrhythmic events and sudden cardiac death**.
7. **Hypertrophic cardiomyopathy** and **arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)** can present as **sudden cardiac death** in young individuals; patients with ARVC/D should **avoid vigorous exercise** and those with risk factors should receive an **implantable cardioverterâ€‘defibrillator**.
8. Firstâ€‘line pharmacologic therapy for **ventricular arrhythmias in ARVC/D** is a **Î²â€‘blocker**; **sotalol, amiodarone,** or **catheter ablation** may be required for recurrent ventricular tachycardia.
9. **Brugada syndrome** treatment includes an **implantable cardioverter-defibrillator (ICD)**, careful avoidance or management of precipitating triggers (for example, certain drugs or fever), and **catheter ablation** in selected patients.
10. **Catecholaminergic polymorphic ventricular tachycardia (CPVT)** presents with syncope and **polymorphic or bidirectional VT** during exercise or emotional distress; optimal management involves **Î²-blockers, verapamil, flecainide, ICD implantation, and strict exercise abstinence**.
11. Prevention of sudden death in **hypertrophic cardiomyopathy (HCM)** may require **ICD placement, Î²-blockers, disopyramide, catheter ablation, or surgical myectomy**.
12. **Long QT syndrome** commonly causes syncope triggered by sleep, auditory stimuli, or exercise (depending on the genetic subtype) and is characterized by a corrected QT interval (**QTc**) usually **> 460 ms** with risk of torsades de pointes ventricular tachycardia.
13. Management of **Long QT syndrome** includes **Î²-adrenergic-receptor blockers (Î²-blockers)** and avoidance of QT-prolonging drugs; selected high-risk patients may additionally require an **implantable cardioverter-defibrillator (ICD)**, left cardiac sympathetic denervation, or exercise restriction.
14. **Brugada syndrome** presents with syncope during sleep or with ventricular fibrillation and shows a coved ST-segment elevation pattern in right-sided precordial leads **Vâ‚â€“Vâ‚ƒ** on electrocardiogram.
15. Primary treatment for **Brugada syndrome** is ICD implantation together with avoidanceâ€”or prompt managementâ€”of precipitating factors such as fever or sodium-channel-blocking drugs; catheter ablation of the right-ventricular outflow-tract substrate may be considered in selected cases.
16. **Catecholaminergic polymorphic ventricular tachycardia (CPVT)** manifests as syncope or polymorphic/bidirectional ventricular tachycardia provoked by physical exercise or emotional distress.
17. Therapy for **CPVT** includes **Î²-blockers** (first-line), with possible addition of **verapamil** or **flecainide**, ICD implantation, and universal avoidance of vigorous exercise.
18. **Arrhythmogenic right-ventricular cardiomyopathy/dysplasia (ARVC/D)** may present with syncope, palpitations, T-wave inversions in leads **Vâ‚â€“Vâ‚ƒ**, monomorphic ventricular tachycardia, frequent premature ventricular complexes, and right-ventricular structural or functional abnormalities on echocardiography or cardiac magnetic resonance imaging (**CMR**).
19. Treatment of **ARVC/D** often involves an ICD, **Î²-blockers**, antiarrhythmic drugs, catheter ablation, and strict avoidance of competitive or high-intensity exercise.
20. **Hypertrophic cardiomyopathy (HCM)** can present with syncope or ventricular fibrillation during exercise and is associated with increased QRS voltage with or without repolarization abnormalities on electrocardiogram.
21. Therapeutic options for **HCM** include ICD placement, **Î²-blockers**, **disopyramide**, septal reduction therapy via catheter ablation, and surgical myectomy.

#### ğŸ’¬ Extra
1. Evaluation typically includes ECG, cardiac imaging, and genetic testing as recommended by current guidelines.
4. QTc thresholds serve as a screening tool but are not diagnostic in isolation.
5. **Î²â€‘Blockers** blunt adrenergic surges that trigger **torsades de pointes** episodes in LQTS.
6. Fever or pharmacologic sodiumâ€‘channel blockade can unmask the Brugada ECG pattern.
9. Comprehensive evaluation for inherited arrhythmia syndromes typically includes ECG, cardiac imaging, and targeted genetic testing.
10. QTc thresholds are useful for screening but are not solely diagnostic because many acquired factors can prolong the QT interval.
11. **Î²-Blockers** blunt adrenergic surges that precipitate torsades de pointes episodes in long-QT syndrome.

#### ğŸ”· Tags
#InheritedArrhythmia #SuddenCardiacDeath #GeneticTesting #BrugadaSyndrome #ARVC #HypertrophicCardiomyopathy

---

#### ğŸ–¼ï¸ Supplemental Figures

<figure>
  <img src="ECG Showing Significant Prolongation of the QT Interval.jpg" alt="ECG showing significant QT prolongation" />
  <figcaption>ECG demonstrating significant prolongation of the QT interval, as well as abnormal morphology, which is best seen in the early precordial leads. Of note, when the heart rate is less than 60/min, the absolute QT interval is routinely used instead of the corrected QT interval (QTc) for heart rate.</figcaption>
</figure>

<figure>
  <img src="ECG Demonstrating a Type 1 Brugada Pattern.jpg" alt="ECG demonstrating a type 1 Brugada pattern" />
  <figcaption>ECG demonstrating a type 1 Brugada pattern, â‰¥2 mm J-point elevation, ST-segment coving (concave or linear downsloping ST segment) and T-wave inversions in leads V1 through V3.</figcaption>
</figure>

---

#### ğŸ—¾ Supplemental Table

<!-- Inherited Syndromes Characterized by Sudden Cardiac Death -->
<table>
  <thead>
    <tr>
      <th>Disorder</th>
      <th>Presenting Symptoms and Characteristic Findings</th>
      <th>Potential Treatments<sup>a</sup></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Long QT syndrome</td>
      <td>Syncope during sleep, auditory triggers, and/or during exercise (depending on subtype); QTc usually &gt;460&nbsp;ms; torsades de pointes</td>
      <td>&beta;-Blockers, avoidance of QT-prolonging drugs; selected patients: ICD, sympathectomy, exercise restriction</td>
    </tr>
    <tr>
      <td>Brugada syndrome</td>
      <td>Syncope during sleep, VF, coved ST-segment elevation in early precordial leads (V<sub>1</sub> through V<sub>3</sub>)</td>
      <td>ICD, avoidance or management of triggers (drugs, fever), catheter ablation</td>
    </tr>
    <tr>
      <td>Catecholaminergic polymorphic VT</td>
      <td>Syncope, polymorphic or bidirectional VT during exercise or emotional distress</td>
      <td>&beta;-Blockers, verapamil, flecainide, ICD, exercise abstinence (uniform)</td>
    </tr>
    <tr>
      <td>Arrhythmogenic right ventricular cardiomyopathy/dysplasia</td>
      <td>Syncope, palpitations, T-wave inversions in leads V<sub>1</sub> through at least V<sub>3</sub>, monomorphic VT, frequent PVCs, and abnormal right-ventricular size and function on echocardiography or CMR imaging</td>
      <td>ICD, &beta;-blockers, antiarrhythmic medications, catheter ablation, exercise abstinence (uniform)</td>
    </tr>
    <tr>
      <td>Hypertrophic cardiomyopathy</td>
      <td>Syncope, VF during exercise, increased QRS voltage with or without repolarization abnormalities on ECG</td>
      <td>ICD, &beta;-blockers, disopyramide, catheter ablation, surgical myectomy</td>
    </tr>
  </tbody>
</table>
<p><em>CMR = cardiac magnetic resonance; ICD = implantable cardioverter-defibrillator; PVC = premature ventricular contraction; QTc = corrected QT interval; VF = ventricular fibrillation; VT = ventricular tachycardia.</em></p>
<p><sup>a</sup> Treatment recommendations for ICD placement in inherited arrhythmia syndromes are guided by risk stratification with criteria that are often disease-specific. Antiarrhythmic drugs are often required for recurrent ventricular arrhythmias.</p>